Completed

A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients

Clinicaltrials.gov Identifier: 

nct00876044

Trial details

Trial date:
April 2009 - February 2010
Phase:  1
Birth sex
Male and female gender symbols.
Age range
18 Years and Older
Accepts healthy volunteers
No
Condition(s) being studied: 

Cancer

What is the type of trial? 

Interventional

What is the trial testing? 

aflibercept (AVE0005), placebo

How many people are being enrolled? 

88

Trial summary

The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients.

Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters, clinical safety and pharmakokinetic (PK) parameters.

Trial locations

location(s)